Posted by slts > 2019-10-04 10:00 | Report Abuse

0.71

Posted by tudungpink > 2019-10-04 18:30 | Report Abuse

senin kne mek 100 taman

Posted by slts > 2019-10-07 08:48 | Report Abuse

ttoday 0.60 wall collapse

Posted by shortinvestor77 > 2019-10-07 09:13 | Report Abuse

Shooting up.

Posted by Up_down > 2019-10-07 09:38 | Report Abuse

Price is still trending upward regardless of small number of voices. Waiting patiently.

Posted by 张晋荣 > 2019-10-07 10:16 | Report Abuse

It will sudden spike up and cross 0.670... watch closely...

Posted by CASHCOWINVESTOR > 2019-10-07 10:52 | Report Abuse

0.68 coming

Posted by HantuRaya2020 > 2019-10-07 12:06 | Report Abuse

Y naik? Got any good announcement we miss?

Posted by Armada An Quantum Leap Stock In 2019/2020 > 2019-10-07 13:37 | Report Abuse

0.760 - 0.815 to be conquered

Posted by Miz Raya Bloom > 2019-10-08 11:57 | Report Abuse

I need vitamins!

Posted by magic01 > 2019-10-08 16:45 | Report Abuse

Nova is now fundamentally and both technically good. Just wait for the good news.

Posted by shortinvestor77 > 2019-10-08 19:34 | Report Abuse

I suggest you attend AGM. You will get a lot of vitamins. Nova had generously given last year.

Posted by Miz Raya Bloom > Oct 8, 2019 11:57 AM | Report Abuse

I need vitamins!

Posted by Miz Raya Bloom > 2019-10-09 09:52 | Report Abuse

I NEED VITAMINS SPECIAL SUPPLEMENTS HEALTHY FOOD. https://www.facebook.com/Nova2U/

Posted by shortinvestor77 > 2019-10-09 11:52 | Report Abuse

GO AGM.

Posted by Miz Raya Bloom > 2019-10-10 09:53 | Report Abuse

merah

Posted by magic01 > 2019-10-10 12:41 | Report Abuse

Now nova edi stay strong. Stay tune.

Posted by Up_down > 2019-10-10 15:39 | Report Abuse

Share price remains trending upward. Go Go Go!

Posted by magic01 > 2019-10-10 17:06 | Report Abuse

Now nova is slowly climbing. Stay tune.

Posted by shortinvestor77 > 2019-10-10 21:03 | Report Abuse

Once Nova product hepar-p passes all clinical tests, the share price will boom a few folds.

Posted by shortinvestor77 > 2019-10-10 21:03 | Report Abuse

http://nova.my/product-details?product=98

Posted by Up_down > 2019-10-11 10:47 | Report Abuse

Why Nova is allowed to sell hepar-p in the market since all clinical tests has not been passed?

shortinvestor77
Once Nova product hepar-p passes all clinical tests, the share price will boom a few folds.
10/10/2019 9:03 PM

Posted by shortinvestor77 > 2019-10-11 17:28 | Report Abuse

The Group recorded revenue of RM9.63 million for the current quarter under review compared to RM8.06 million for the
preceding quarter. The increase of 19.5% was mainly due to higher sales contribution from House Brand segment under
the functional food category namely ActivMax and sales contribution from clinical trial for Hepar-P.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/6263521

Posted by shortinvestor77 > 2019-10-11 17:32 | Report Abuse

Clinical trial of Hepar-P Capsule ( is for the treatment of non-alcoholic fatty liver disease.
2015
Completed the first clinical trial of Hepar-P Capsule for the treatment of non-alcoholic fatty liver disease.
2017
Ready for the second clinical trial of Hepar-P Capsule for the treatment of non-alcoholic fatty liver disease.
http://nova.my/history

Posted by shortinvestor77 > 2019-10-11 17:36 | Report Abuse

as natural supplement without harm, no problem, it can be sold. But to prove its effectiveness to cure a disease, clinical test is needed for the product in order to claim it.

Posted by shortinvestor77 > 2019-10-11 17:40 | Report Abuse

Nova uses Phyllanthus niruri (dukung anak) (easily found in Malaysia) for Hepar-P capsule.
Liver care is as complex as the liver itself. Hepar-P is a natural liver tonic agent, formulated with a standardized extract of Phyllanthus niruri and holds two Malaysian patents. Hepar-P provides a consistent dose of the functional actives, responsible for protecting the liver from injury.
http://nova.my/product-details?product=154

Posted by Up_down > 2019-10-11 18:07 | Report Abuse

It may take years to get through 5 phases clinical trials .

Phases of clinical trials
A clinical trial is only done when there is good reason to believe that a new test or treatment may improve the care of patients. Before clinical trials, tests and treatments are assessed in preclinical research. Preclinical research is not done with people. It assesses the features of a test or treatment. For example, the research may aim to learn if a device is harmful to living tissue. Another aim may be to learn more about the chemical makeup of a drug.

After preclinical research, tests and treatments go through a series of clinical trials. Clinical trials assess if tests or treatments are safe for and work in people. Clinical trials have five phases. The phases are described next using the example of a new drug treatment:

Phase 0
Phase 0 trials are the first clinical trials done among people. They aim to learn how a drug is processed in the body and how it affects the body. In these trials, a very small dose of a drug is given to about 10 to 15 people.

Phase I
Phase I trials aim to find the best dose of a new drug with the fewest side effects. The drug will be tested in a small group of 15 to 30 patients. Doctors start by giving very low doses of the drug to a few patients. Higher doses are given to other patients until side effects become too severe or the desired effect is seen. The drug may help patients, but Phase I trials are to test a drug’s safety. If a drug is found to be safe enough, it can be tested in a phase II clinical trial.

Phase II
Phase II trials further assess safety as well as if a drug works. The drug is often tested among patients with a specific type of cancer. Phase II trials are done in larger groups of patients compared to Phase I trials. Often, new combinations of drugs are tested. Patients are closely watched to see if the drug works. However, the new drug is rarely compared to the current (standard-of-care) drug that is used. If a drug is found to work, it can be tested in a phase III clinical trial.

Phase III
Phase III trials compare a new drug to the standard-of-care drug. These trials assess the side effects of each drug and which drug works better. Phase III trials enroll 100 or more patients.

Often, these trials are randomized. This means that patients are put into a treatment group, called trial arms, by chance. Randomization is needed to make sure that the people in all trial arms are alike. This lets scientists know that the results of the clinical trial are due to the treatment and not differences between the groups. A computer program is often used to randomly assign people to the trial arms.

There can be more than two treatment groups in phase III trials. The control group gets the standard-of-care treatment. The other groups get a new treatment. Neither you nor your doctor can choose your group. You will also not know which group you’re in until the trial is over.

Every patient in a phase III study is watched closely. The study will be stopped early if the side effects of the new drug are too severe or if one group has much better results. Phase III clinical trials are often needed before the FDA will approve the use of a new drug for the general public.

Phase IV
Phase IV trials test new drugs approved by the FDA. The drug is tested in several hundreds or thousands of patients. This allows for better research on short-lived and long-lasting side effects and safety. For instance, some rare side effects may only be found in large groups of people. Doctors can also learn more about how well the drug works and if it’s helpful when used with other treatments.

Posted by Up_down > 2019-10-11 18:21 | Report Abuse

If Hepar-P is able to complete 3rd clinical trials, MNC may come to take over Nova. lolz

Posted by shortinvestor77 > Oct 11, 2019 5:32 PM | Report Abuse

Clinical trial of Hepar-P Capsule ( is for the treatment of non-alcoholic fatty liver disease.
2015
Completed the first clinical trial of Hepar-P Capsule for the treatment of non-alcoholic fatty liver disease.
2017
Ready for the second clinical trial of Hepar-P Capsule for the treatment of non-alcoholic fatty liver disease.
http://nova.my/history

Posted by shortinvestor77 > 2019-10-11 21:41 | Report Abuse

Nova Wellness bosses have a large portion of shares, unabled to be taken over easily by multi national companies lah. Anyhow, they can start buying now aa you can see the share price is uptrend.

Posted by Armada An Quantum Leap Stock In 2019/2020 > 2019-10-11 21:48 | Report Abuse

Up down sifu
Give you 1 like
For the facts sharing

Posted by Up_down > 2019-10-14 11:12 | Report Abuse

Share price up like nobody business. First TP 76 cents.

Posted by Armada An Quantum Leap Stock In 2019/2020 > 2019-10-15 10:01 | Report Abuse

New high
Sky is d limit

Posted by CASHCOWINVESTOR > 2019-10-15 10:10 | Report Abuse

Buy before regret

Posted by Armada An Quantum Leap Stock In 2019/2020 > 2019-10-17 00:55 | Report Abuse

Today closing at 0.630 

Firm support at 0.600 
Immediate target to hit 0.710 

Risk over Reward : 1 to 3 
The probability of win is more than your meal for a day. 
In another word, entry at 0.630 u chance to win just like eating lettuce. 

WHO DON'T LIKE LETTUCE ?

Posted by Armada An Quantum Leap Stock In 2019/2020 > 2019-10-17 18:29 | Report Abuse

0.600 lai liaow

Posted by cheer76 > 2019-10-17 23:10 | Report Abuse

topup

Posted by Armada An Quantum Leap Stock In 2019/2020 > 2019-10-18 09:58 | Report Abuse

Nova making a return again
Real good

Posted by Up_down > 2019-10-18 11:09 | Report Abuse

Financial facts of Nova Wellness:
Price: 0.64
PER: 21x
Gearing: Nil
Dividend yield: 3.6% ( 2.3 cents per share)

Net cash generated from operating activities:
FY 30 Jun 2019 - 13.3m
FY 30 Jun 2018 - 7.1m

PAT
30 Sep 19 - ???
30 Jun 19 - 3.71m ( excluding IPO expenses, reversal of slow moving stock & interest received)
31 Mar 19 - 2.03m
31 Dec 18 - 3.08m
30 Sep 18 - 0.85m
30 Jun 18 - 2.41m
31 Mar 18 - 1.38m

Turnover
30 Sep 19 - ???
30 Jun 19 - 9.6m
31 Mar 19 - 7.2m
31 Dec 18 - 7.9m
30 Sep 18 - 4.8m
30 Jun 18 - 8.1m
31 Mar 18 - 4.7m

Posted by LiimInvest > 2019-10-21 17:15 | Report Abuse

Turnover
30 Sep 19 - ??? sure increase

Posted by cheer76 > 2019-10-21 19:47 | Report Abuse

80cents please

Posted by Up_down > 2019-10-22 11:07 | Report Abuse

Extract from prospectus:

2nd clinical trial:
We initiated the second clinical trial for Hepar-P Capsule in December 2017 and are expected to complete in December 2019. The second clinical trial is to allow for a specific claim on the effectiveness of Hepar-P Capsule for the improvement of liver health. The second trial involves patients with non-alcoholic fatty liver as well and will be administered to a larger group of participants of approximately 200 participants to further evaluate its effectiveness for liver health.

3rd clinical trial:
Third clinical trial for Hepar-P Capsule as liver protection agent;
We expect to begin the third clinical trial for Hepar-P Capsule in October 2019 and to complete in December 2020. The third clinical trial involves patients with drug induced liver injury. The third clinical trial will be administered to a larger group of participants of approximately 300 participants to further evaluate the product’s effectiveness. The third clinical trial will be a 6-month trial involving participants with elevated liver enzymes level. If the trial is successful and Hepar-P Capsule is clinically proven to be effective, the third clinical trial will allow for more empirical data to be obtained to further promote and strengthen the product positioning as a liver protection agent.

Posted by shortinvestor77 > 2019-10-22 13:21 | Report Abuse

Good.

Posted by Armada An Quantum Leap Stock In 2019/2020 > 2019-10-22 14:33 | Report Abuse

Lai lioaw

Posted by Up_down > 2019-10-22 14:47 | Report Abuse

1st clinical trial:

The first clinical trial was completed in January 2015. Our CRO has presented us the final report of the study. From the first clinical trial, Hepar-P Capsule was proven was proven safe for long term consumption with no adverse effects reported in patients. However, the efficacy could not be concluded as not all the patients consented to the liver biopsy at the end of the clinical trial. Only 6 patients out of the 50 patients consented to repeat the liver biopsy at the end of the clinical trial. The 6 patients showed improvement in liver enzymes. The major limitation of the first clinical trial is the relatively small sample size (50 patients) and the biopsy was not repeated for most of the patients after the completion of the treatment.

Posted by kkwn1718 > 2019-10-22 20:46 | Report Abuse

May I know how was the performance of Nova in past two weeks?

Posted by Samtuckfatt > 2019-10-22 23:36 | Report Abuse

Kkwn1718.

https://www.klsescreener.com/v2/stocks/view/0201 , click the historical price

Posted by Up_down > 2019-10-23 14:38 | Report Abuse

New GMP factory:
Upon completion of the new GMP-compliant production facility, our production capacity for functional food is expected to increase from 0.69 million bottles and 0.69 million sachets to 3.43 million bottles and 3.43 million sachets.

The construction of the new GMP Plant had commenced in August 2017 and Phase 1 is expected to be completed by September 2019. Construction of Phase 2 will commence after completion of Phase 1.

Clinical trials on Ficus Cream products for skin lightening and We have completed the pre-clinical trial on Ficus microcarpa standardised extract contained in Ficus Cream products in 2016. We intend to undertake two clinical trials for Ficus Cream products in September 2019 and to complete both by July 2020. The clinical trials are to evaluate the effectiveness and safety of Ficus Cream for skin lightening and to explore other anti-ageing properties. The trials will be conducted on two different formulations containing the Ficus microcarpa standardised extract. Each clinical trial will be an 8-week trial and will involve a group of approximately 50 participants.

If the trials are successful and Ficus Cream products are clinically proven to be effective and safe for skin lightening, we expect to strengthen the products positioning as a skin lightening agent.

Posted by LiimInvest > 2019-10-23 17:29 | Report Abuse

Up_down-thanks for your sharing. Great info.

Posted by Up_down > 2019-10-23 20:02 | Report Abuse

https://clinicalresearch.my/the-journey-of-a-clinician-researcher-on-nafld-in-malaysia-from-epidemiology-to-non-invasive-assessment-to-treatment/

Epidemiology of NAFLD

The prevalence of NAFLD in the general population was estimated to be 23% based on a study using ultrasonography on health check individuals in a private medical centre in Petaling Jaya about a decade ago.(2)“The work by Professor Dato Dr. Goh Khean Lee and his colleagues, provided primary data on the estimated prevalence of NAFLD in the general population in Malaysia,” said Dr. Chan. Recently, the prevalence of NAFLD was found to be 57% based on a study using Fibroscan on health check individuals in a public medical facility in Kuala Lumpur. The study also found that 18% of the individuals had liver stiffness measurement consistent with excessive scarring in the liver.(3)“The figures from our latest work are indeed worrisome. More concerted efforts are needed to tackle obesity and obesity-related disease such as NAFLD,” he said. The group also reported that half of the patients with diabetes mellitus seen at their hospital clinic had NAFLD,(4)and 8% of the students at their faculty had NAFLD.(5)

Posted by Up_down > 2019-10-23 20:16 | Report Abuse

Dealing with fatty liver
https://www.pressreader.com/malaysia/the-star-malaysia-star2/20180417/282089162360026

" More new drugs emerge ever day, but even promising ones such as glucagon-like-peptide-1 receptor agonist are still in testing or trail stages....

Posted by LiimInvest > 2019-10-25 23:28 | Report Abuse

FINAL SINGLE TIER DIVIDEND OF 0.6 SEN PER SHARE IN RESPECT OF FINANCIAL YEAR ENDED 30 JUNE 2019